Systemic sclerosis. A vascular perspective

The horizon is bright for SSc in a vascular context. Surrogate markers can now be routinely used in the management of the active patient; new cytokines, such as VEGF, can be studied along with the known abnormalities of the cytokine cascade (TGF beta 1, PDGF) for a more integrated understanding of t...

Full description

Saved in:
Bibliographic Details
Published inRheumatic diseases clinics of North America Vol. 22; no. 4; p. 675
Main Author LeRoy, E C
Format Journal Article
LanguageEnglish
Published United States 01.11.1996
Subjects
Arteries - pathology
Autoantibodies - physiology
Cell Adhesion Molecules - physiology
Endothelium, Vascular - pathology
Humans
Mast Cells - pathology
Mast Cells - physiology
Microcirculation - immunology
Microcirculation - pathology
Neovascularization, Physiologic
Raynaud Disease - physiopathology
Scleroderma, Systemic - etiology
Scleroderma, Systemic - immunology
Scleroderma, Systemic - pathology
Scleroderma, Systemic - physiopathology
T-Lymphocytes - physiology
Vascular Diseases - physiopathology
Online AccessGet more information

Cover

More Information
Summary:The horizon is bright for SSc in a vascular context. Surrogate markers can now be routinely used in the management of the active patient; new cytokines, such as VEGF, can be studied along with the known abnormalities of the cytokine cascade (TGF beta 1, PDGF) for a more integrated understanding of the vascular pathogenesis of SSc (Fig. 6); and combination therapies can be applied before vascular insufficiency leads to vital organ failure. Thus, despite reimbursement and research funding constraints, the future for both the SSc patient and the investigator of SSc is optimistic when based on a firm biologic foundation.
ISSN:0889-857X
1558-3163
DOI:10.1016/S0889-857X(05)70295-7